1,2-di-[3-(N-vinylformamido)propionamido]ethane | 202114-72-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,2-di-[3-(N-vinylformamido)propionamido]ethane
• 英文别名: 3-[ethenyl(formyl)amino]-N-[2-[3-[ethenyl(formyl)amino]propanoylamino]ethyl]propanamide
• CAS: 202114-72-5
• 化学式: C₁₄H₂₂N₄O₄
• 分子量: 310.353
• InChiKey: GCOOLAMKHFWFII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  98.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  ethyl 3-(N-vinylformamido)propionate 、 N,N-di-(2-hydroxyethyl) 3-(N-vinylformamido)propionamide 在 sodium methylate 、 乙二胺 作用下， 以 甲醇 为溶剂， 生成 1,2-di-[3-(N-vinylformamido)propionamido]ethane
  参考文献：
  名称：

  Functional N-vinylformamides

  摘要：

  通过将相应的丙酸酯与适当的烷胺进行酰胺化反应，得到包含3-(N-乙烯基甲酰胺基)丙酰胺和2-甲基-3-(N-乙烯基甲酰胺基)丙酰胺，其中含有末端氨基、羟基或第二个N-乙烯基的N-乙烯基组成物。该发明还描述了制备这些化合物的方法。这些材料可用作自由基聚合中的单体，也可用作制备不饱和树脂的前体。

  公开号：

  US05728878A1

文献信息

• TREATING HYPERKALEMIA WITH CROSSLINKED CATION EXCHANGE POLYMERS OF IMPROVED PHYSICAL PROPERTIES
  申请人：Mansky Paul

  公开号：US20100104527A1

  公开（公告）日：2010-04-29

  The present invention is directed to methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio.

  本发明涉及通过给予交联阳离子交换聚合物的药物组合物来除去钾或治疗高钾血症的方法。该药物组合物具有有益的物理特性，包括颗粒大小、颗粒形状、颗粒大小分布、粘度、屈服应力、可压缩性、表面形态和/或肿胀比的组合。
• CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA
  申请人：Mansky Paul

  公开号：US20110236340A1

  公开（公告）日：2011-09-29

  The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract.

  本发明涉及交联的带有氟基和酸基的阳离子交换聚合物，这些聚合物的药物组成物，线性多元醇和这种聚合物的盐的组成物。还描述了具有有益物理特性的交联阳离子交换聚合物，包括粒径、粒子形状、粒径分布、粘度、屈服应力、可压缩性、表面形态和/或肿胀比的组合。这些聚合物和组成物有助于在胃肠道中结合钾。
• Functional N-vinylformamides, process for their preparation and their use in free radical polymerisation reactions
  申请人：AIR PRODUCTS AND CHEMICALS, INC.

  公开号：EP0816351A1

  公开（公告）日：1998-01-07

  N-vinyl compositions comprising 3-(N-vinylformamido)propionamides and 2-methyl-3-(N-vinylformamido)propionamides containing terminal amino, hydroxyl or a second N-vinyl group are obtained by amidation of the corresponding propionate ester with appropriate alkylamines. The invention also describes a process for preparing these compounds. The subject materials are useful as monomers in free radical polymerization as well as precursors in the preparation of unsaturated resins.

  通过用适当的烷基胺对相应的丙酸酯进行酰胺化反应，可获得由含有末端氨基、羟基或第二个 N-乙烯基的 3-(N-乙烯基甲酰氨基)丙酰胺和 2-甲基-3-(N-乙烯基甲酰氨基)丙酰胺组成的 N-乙烯基组合物。本发明还描述了制备这些化合物的工艺。上述材料可用作自由基聚合的单体以及制备不饱和树脂的前体。
• Ion binding polymers and uses thereof
  申请人：Vifor (International) Ltd.

  公开号：US10485821B2

  公开（公告）日：2019-11-26

  The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

  本发明提供了治疗离子失衡的方法和组合物。特别是，本发明提供了包含钾结合聚合物的组合物及其药物组合物。本文公开了聚合物和药物组合物用于治疗和/或预防的方法。这些方法的例子包括治疗高钾血症，如肾功能衰竭引起的高钾血症和/或使用引起高钾血症的药物。
• Potassium-binding agents for treating hypertension and hyperkalemia
  申请人：Vifor (International) Ltd.

  公开号：US11123363B2

  公开（公告）日：2021-09-21

  The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.

  本发明一般涉及治疗有需要的患者的高血压（HTN）的方法，其中患者可选择进一步患有慢性肾病（CKD）或II型糖尿病（T2DM）。本发明还涉及在有需要的患者中治疗高钾血症的方法，其中患者患有 CKD、T2DM 或 HTN，并可选择使用有效量的肾素-血管紧张素-醛固酮系统（RAAS）制剂进行治疗。本发明还涉及治疗有需要的患者肾脏疾病的方法，其中患者可选择使用有效量的肾素-血管紧张素-醛固酮系统（RAAS）制剂进行治疗。这些方法可包括向患者施用有效量的钾结合剂，以降低患者的血压和/或增加或稳定患者的肾功能。